RVL Pharmaceuticals plc Annual Current Federal Tax Expense (Benefit) in USD from 2017 to 2022

Taxonomy & unit: us-gaap: USD
Description: Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary: RVL Pharmaceuticals plc quarterly/annual Current Federal Tax Expense (Benefit) history and growth rate from 2017 to 2022.
RVL Pharmaceuticals plc Current Federal Tax Expense (Benefit) for the quarter ending March 31, 2023 was $4.1M.
RVL Pharmaceuticals plc annual Current Federal Tax Expense (Benefit) for 2022 was -$86K, a 55.2% increase from 2021.
RVL Pharmaceuticals plc annual Current Federal Tax Expense (Benefit) for 2021 was -$192K, a 105% decline from 2020.
RVL Pharmaceuticals plc annual Current Federal Tax Expense (Benefit) for 2020 was $4.15M.

Current Federal Tax Expense (Benefit), Annual (USD)

Current Federal Tax Expense (Benefit), YoY Annual Growth (%)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
2022	-$86K	+$106K	+55.2%	Jan 1, 2022	Dec 31, 2022	10-K	2023-03-20
2021	-$192K	-$4.34M	-105%	Jan 1, 2021	Dec 31, 2021	10-K	2023-03-20
2020	$4.15M	+$21.1M		Jan 1, 2020	Dec 31, 2020	10-K	2022-03-30
2019	-$17M	-$19.9M	-685%	Jan 1, 2019	Dec 31, 2019	8-K	2021-09-08
2018	$2.9M	+$1.16M	+66.3%	Jan 1, 2018	Dec 31, 2018	10-K	2020-03-19
2017	$1.75M			Jan 1, 2017	Dec 31, 2017	8-K	2019-12-20

Showing 1 to 6 of 6 entries

* An asterisk sign (*) next to the value indicates that the value is likely invalid.